INVO Fertility, Inc.
Business
INVO Fertility, Inc. is a healthcare services company focused on the fertility marketplace that builds, acquires, and operates fertility clinics to expand access to assisted reproductive technology (ART). It offers clinical fertility services including intravaginal culture (IVC) using the INVOcell® medical device, in vitro fertilization (IVF), intrauterine insemination (IUI) and related clinic-based services, and distributes INVOcell to third‑party clinics. Its key business segments include Fertility Clinics, the INVOcell Device, and a Therapeutics segment (NAYA Therapeutics). The company primarily operates in the United States through wholly owned clinics, joint ventures, direct sales to clinics, and partnerships while remaining open to selective international distribution relationships.
Summary from filing dated 2025-04-30
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Total revenue | 7 | 7 | 3 | — | — | |
| Cost of services | 4 | 4 | 2 | — | — | |
| Cost of goods sold | 30,571 | 12,201 | — | 286,923 | 126,326 | |
| Selling, general and administrative expenses | 8 | 8 | 7 | 10 | 9 | |
| Research and development expenses | — | 4,880 | 165,945 | 544,043 | 216,430 | |
| Impairment of intangible assets | 1 | — | — | — | — | |
| Loss on disposal of fixed assets | — | 511,663 | — | — | — | |
| Depreciation and amortization | 677,364 | 919,603 | 200,894 | 77,301 | — | |
| Total operating expenses | 14 | 13 | — | — | — | |
| Loss from operations | −7 | −7 | −7 | −11 | −5 | |
| Gain from equity method joint ventures | 31,294 | 9,045 | −60,270 | −200,558 | — | |
| Gain on changes in fair value | 5 | — | — | — | — | |
| Gain on lease termination | — | 94,551 | — | — | — | |
| Loss from debt extinguishment | −2 | −40,491 | −163,278 | — | 159,126 | |
| Loss on issuance of warrants | −943,862 | — | — | — | — | |
| Gain on settlement of liability (Note 18) | 929,500 | — | — | — | — | |
| Interest expense | −1 | −1 | −925,909 | — | — | |
| Total other income (expenses) | 2 | −972,038 | −1 | −263,158 | −1 | |
| Net loss before income taxes | −5 | −8 | −8 | −11 | −7 | |
| Provision (benefit) for income taxes | −150,371 | 140,202 | 27,786 | 2,872 | 4,764 | |
| Net loss from continuing operations | −5 | −8 | — | — | — | |
| Loss on disposal of NTI (Note 4) | −2 | — | — | — | — | |
| Loss on discontinued operations of NTI (Note 4) | −16 | −2 | — | — | — | |
| Net loss | −23 | −9 | −8 | −11 | −7 | |
| Preferred stock dividends and deemed dividends | −2 | −250,635 | — | — | — | |
| Net loss attributable to common shareholders | −25 | −10 | −8 | — | — | |
| Basic | −45.57 | −3,079 | — | — | — | |
| Diluted | −45.57 | −3,079 | — | — | — | |
| Basic | −153.63 | −604.21 | — | — | — | |
| Diluted | −153.63 | −604.21 | — | — | — | |
| Basic (per share) | −214.64 | −3,783 | −67.37 | −17.97 | −0.63 | |
| Diluted (per share) | −214.64 | −3,783 | −67.37 | −17.97 | −0.63 | |
| Basic (shares) | 117,083 | 2,514 | 119,264 | 606,130 | 11 | |
| Diluted (shares) | 117,083 | 2,514 | 119,264 | 606,130 | 11 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2025 2025-09-30 | FY 2025 2025-06-30 | FY 2025 2025-03-31 | FY 2024 2024-12-31 |
|---|---|---|---|---|---|---|
| Cash | 2 | — | — | — | 619,520 | |
| Accounts receivable, net of allowances of $69,641 and $61,773 as of December 31, 2025 and 2024, respectively | 217,263 | — | — | — | 113,108 | |
| Inventory | 225,253 | — | — | — | 219,764 | |
| Prepaid expenses and other current assets | 241,145 | — | — | — | 180,853 | |
| Current assets held for disposition | — | — | — | — | 123,313 | |
| Total current assets | 3 | — | — | — | 1 | |
| Property and equipment, net | 386,165 | — | — | — | 466,684 | |
| Lease right of use | 1 | — | — | — | 1 | |
| Intangible assets, net | 1 | — | — | — | 3 | |
| Goodwill | 6 | — | — | — | 6 | |
| Investment in NAYA Therapeutics | 2 | — | — | — | — | |
| Noncurrent assets held for disposition | — | — | — | — | 32 | |
| Total assets | 20 | — | — | — | 46 | |
| Accounts payable and accrued liabilities | 2 | — | — | — | 3 | |
| Accrued compensation | 285,946 | — | — | — | 713,483 | |
| Deferred revenue | 721,897 | — | — | — | 602,359 | |
| Lease liability, current portion | 208,987 | — | — | — | 181,132 | |
| Additional payments for acquisition, current portion | 4 | 4 | 5 | — | 3 | |
| Derivative liability | 2 | 256,034 | 815,897 | — | — | |
| Other current liabilities | — | — | — | — | 410,000 | |
| Current liabilities held for disposition | — | — | — | — | 4 | |
| Total current liabilities | 10 | 9 | 12 | — | 18 | |
| Lease liability, net of current portion | 1 | — | — | — | 1 | |
| Liability for excess losses of equity method investee | 448,474 | — | — | — | 479,768 | |
| Notes payable net of current portion | 744,725 | — | — | — | 1 | |
| Deferred tax liability | — | — | — | — | 163,115 | |
| Additional payments for acquisition, net of current portion | 300,000 | 950,000 | 950,000 | — | 5 | |
| Total liabilities | 13 | 13 | 16 | — | 26 | |
| Series C-2 Preferred Stock (mezzanine) $1,000.00 par value; 20,000 shares authorized; 3,004 and 8,576 issued and outstanding as of December 31, 2025 and 2024, respectively. | — | — | 10 | 34 | 7 | |
| Common Stock, $.0001 par value; 6,250,000 shares authorized; 477,366 and 3,111 issued and outstanding as of December 31, 2025 and 2024, respectively | 239 | — | — | — | 37 | |
| Additional paid-in capital | 96 | 89 | 82 | — | 50 | |
| Accumulated deficit | −91 | −92 | −89 | — | −67 | |
| Total stockholders equity | 7 | 6 | −7 | −27 | 13 | |
| Total liabilities, mezzanine, and stockholders equity | 20 | — | — | — | 46 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Non-cash stock compensation issued for services | 1 | 1 | 287,450 | 123,211 | — | |
| Non-cash stock compensation issued to directors and/or employees | — | 153 | 56,936 | 484,807 | 360,153 | |
| Fair value of stock options issued to employees | 178,729 | 342,728 | 1 | 2 | — | |
| Non-cash compensation for services | 135,000 | 180,000 | 180,000 | 120,000 | — | |
| Amortization of discount on notes payable | 1 | 622,283 | 720,128 | 52,644 | 1 | |
| Impairment loss | 16 | — | — | — | — | |
| Reserve on other assets | — | 498,592 | — | — | — | |
| Loss on disposal of fixed assets | — | 511,663 | — | — | — | |
| Loss on disposition | 2 | — | — | — | — | |
| Gain on settlement | −929,500 | — | — | — | — | |
| Depreciation and amortization | 677,364 | 919,603 | 200,894 | 77,301 | 27,760 | |
| Accounts receivable | −104,155 | 27,442 | −63,401 | −26,679 | −28,771 | |
| Inventory | −5,489 | 44,743 | −905 | 24,171 | −22,401 | |
| Prepaid expenses and other current assets | −120,472 | −163,761 | −432,093 | 92,550 | −124,811 | |
| Equity investments | — | 4,534 | — | — | — | |
| Accounts payable and accrued expenses | −1 | 1 | 924,678 | 904,060 | 114,495 | |
| Accrued compensation | −153,265 | 274,665 | −224,011 | 364,573 | 54,363 | |
| Deferred revenue | 119,538 | 193,590 | 288,893 | 113,976 | −4 | |
| Other current liabilities | −60,000 | — | −226,568 | — | — | |
| Leasehold liability | 10,721 | −35,904 | 85,191 | 7,026 | −53,846 | |
| Accrued interest | 119,095 | 166,772 | 121,864 | 1,556 | 20,921 | |
| Deferred tax liabilities | −163,115 | 163,115 | — | — | −392 | |
| Net cash used in operating activities | −7 | −3 | −5 | −7 | −6 | |
| Payments to acquire property, plant, and equipment | −43,412 | −183,703 | −444,722 | −10,785 | −415,710 | |
| Proceeds from sale of fixed assets | — | 75,590 | — | — | — | |
| Cash acquired in acquisition | — | 472,008 | — | — | — | |
| Divesture of NTI | −6,569 | — | — | — | — | |
| Payment for acquisitions | −3 | — | — | — | — | |
| Net cash used in investing activities | −3 | 363,895 | −2 | −81,217 | −2 | |
| Proceeds from notes payable | — | 1 | — | — | — | |
| Proceeds from the sale of common stock, net of offering costs | 12 | 200,000 | 6 | 300,000 | 4 | |
| Proceeds from the sale of preferred stock | 3 | 2 | — | — | — | |
| Proceeds from warrant exercise | 1 | 900,611 | 23,051 | — | 123,562 | |
| Preferred stock redemption | −4 | — | — | — | — | |
| Principal payments on notes payable | −1 | −934,419 | −1 | — | −250,000 | |
| Net cash provided by financing activities | 11 | 3 | 7 | 1 | 4 | |
| Increase in cash and cash equivalents | 1 | 508,972 | 142,289 | −6 | −4 | |
| Interest | 644,158 | 214,742 | 9,640 | — | 52,603 | |
| Taxes | — | — | — | 800 | 3,307 | |
| Fair value of preferred stock issued for acquisition | — | 25 | — | — | — | |
| Common stock and preferred stock issued upon conversion notes payable and accrued interest | 5 | 387,033 | — | — | — | |
| Dividends on preferred stock | 718,616 | — | — | — | — | |
| Deemed dividend | 1 | 250,635 | — | — | — | |
| Fair value of warrants issued with debt | 167,863 | 188,755 | 490,668 | 90,000 | — | |
| C-2 to common stock exchange | 14 | — | — | — | — | |
| Preferred stock redemption adjustment | 521,922 | — | — | — | — | |
| Preferred stock exchange | 1 | — | — | — | — | |
| Common stock issued for accounts payable | 23,460 | — | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is INVO Fertility, Inc.'s CIK number?
INVO Fertility, Inc.'s SEC CIK number is 0001417926 (1417926). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find INVO Fertility, Inc.'s SEC filings?
All of INVO Fertility, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did INVO Fertility, Inc. last report earnings?
INVO Fertility, Inc. (IVF) most recently filed an earnings 8-K with the SEC on Jun 22, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001493152-26-029517). This is INVO Fertility, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is INVO Fertility, Inc.'s most recent earnings 8-K?
INVO Fertility, Inc.'s latest earnings 8-K (Item 2.02) was filed Jun 22, 2026 under accession 0001493152-26-029517. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View INVO Fertility, Inc.'s latest earnings 8-K →
Look up any company's CIK number →